MOG and myeloid sarcoma: Because the MOG‐EAE model used in the current study more closely recapitulates the chronic progressive disease profile, IndCl treatment has the potential to improve VEP latencies in chronic progressive MS, a result that has not been shown with current approved MS drugs.